Scarica l'app Stockscreener
11.32
0.96%
-0.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AUPH Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$11.43
Aprire:
$11.47
Volume 24 ore:
2.34M
Relative Volume:
1.25
Capitalizzazione di mercato:
$1.49B
Reddito:
$175.51M
Utile/perdita netta:
$-78.02M
Rapporto P/E:
-21.36
EPS:
-0.53
Flusso di cassa netto:
$-34.18M
1 W Prestazione:
-3.25%
1M Prestazione:
+28.64%
6M Prestazione:
+44.94%
1 anno Prestazione:
+107.33%
Intervallo 1D:
$11.29
$11.59
Intervallo di 1 settimana:
$11.26
$11.79
Portata 52W:
$5.37
$11.80
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Nome
Aurinia Pharmaceuticals Inc
Settore
Industria
Telefono
250-744-2487
Indirizzo
#140, 14315 - 118 AVENUE, EDMONTON, BC
Confronta AUPH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
11.32 | 1.50B | 175.51M | -78.02M | -34.18M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Ripresa | H.C. Wainwright | Buy |
| 2022-11-04 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-05-05 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-05-05 | Iniziato | Cowen | Outperform |
| 2020-01-10 | Iniziato | Jefferies | Buy |
| 2019-12-16 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-16 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-02-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-10-30 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-03-22 | Reiterato | FBR & Co. | Outperform |
| 2016-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-17 | Reiterato | H.C. Wainwright | Buy |
| 2016-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2015-05-08 | Iniziato | MLV & Co | Buy |
Mostra tutto
Aurinia Pharmaceuticals Inc Borsa (AUPH) Ultime notizie
Can machine learning forecast Aurinia Pharmaceuticals Inc. recoveryShort Squeeze Opportunities with Indicators - Newser
Zurcher Kantonalbank Zurich Cantonalbank Acquires 8,390 Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) - Defense World
Full technical analysis of Aurinia Pharmaceuticals Inc. stockFree Early Entry Tips With Low Risk Zone - Newser
What data driven models say about Aurinia Pharmaceuticals Inc.’s futureFree Expert Verified Stock Trade Ideas - Newser
Will Aurinia Pharmaceuticals Inc. stock go up soonHigh Conviction Stock Long-Term Summary - Newser
Aurinia Pharmaceuticals Reports Strong Q2 2025 Financial Results and Expands Share Repurchase Plan - MSN
Is Aurinia Pharmaceuticals Inc. stock ready for a breakoutHigh Probability Trade Outcome Prediction - Newser
Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade) (NASDAQ:AUPH) - Seeking Alpha
Aurinia (AUPH) Q2 Revenue Jumps 22% - AOL.com
Day 6 of Gains Streak for Aurinia Pharmaceuticals Stock with 32% Return (vs. 30% YTD) [8/5/2025] - Trefis
Major Moves in Aurinia Pharmaceuticals Stock: Insider Trading Unveiled - TipRanks
Aurinia Pharma director Tang buys $13.59m in shares - Investing.com India
Aurinia Pharma director Tang buys $13.59m in shares By Investing.com - Investing.com Canada
Aurinia Pharmaceuticals Reaches Analyst Target Price - Nasdaq
Aurinia Pharmaceuticals (NASDAQ:AUPH) Reaches New 12-Month High on Analyst Upgrade - Defense World
Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Aurinia Pharmaceuticals stock hits 52-week high at 10.74 USD By Investing.com - Investing.com South Africa
Aurinia Pharmaceuticals stock hits 52-week high at 10.74 USD - Investing.com
Research Analysts Set Expectations for AUPH FY2026 Earnings - Defense World
Aurinia Pharmaceuticals: Strong Financial Performance and Promising Pipeline Drive Buy Rating - TipRanks
What is Leerink Partnrs’ Forecast for AUPH Q1 Earnings? - Defense World
What are the latest earnings results for Aurinia Pharmaceuticals Inc.Unprecedented profit potential - Jammu Links News
Published on: 2025-08-04 03:37:38 - Jammu Links News
What analysts say about Aurinia Pharmaceuticals Inc. stockCapitalize on emerging investment opportunities - Jammu Links News
What is the risk reward ratio of investing in Aurinia Pharmaceuticals Inc. stockBuild a portfolio that outperforms the market - Jammu Links News
Is it the right time to buy Aurinia Pharmaceuticals Inc. stockAchieve superior capital gains with smart trades - Jammu Links News
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Just Beat EPS By 9.1%: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Aurinia raises 2025 revenue outlook to $270M as LUPKYNIS accelerates market penetration - MSN
What catalysts could drive Aurinia Pharmaceuticals Inc. stock higher in 2025Unlock rapid growth potential in your portfolio - Jammu Links News
What drives Aurinia Pharmaceuticals Inc. stock priceFree Stock Market Mentorship - Jammu Links News
Should I hold or sell Aurinia Pharmaceuticals Inc. stock in 2025Free Investment Portfolio Suggestions - Jammu Links News
What are the technical indicators suggesting about Aurinia Pharmaceuticals Inc.Rapid growth opportunities - Jammu Links News
What is Aurinia Pharmaceuticals Inc. company’s growth strategyFastest-growing stock picks - Jammu Links News
How does Aurinia Pharmaceuticals Inc. generate profit in a changing economyRetirement Planning Forecasts For Consistent Profits - jammulinksnews.com
Aurinia Pharmaceuticals (AUPH): A High-Growth Biopharma Play with Strong Earnings Momentum and Strategic Pipeline Expansion - AInvest
Aurinia Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Published on: 2025-08-02 11:34:23 - beatles.ru
Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading 6.1% Higher After Analyst Upgrade - Defense World
Q2 Earnings Estimate for AUPH Issued By HC Wainwright - Defense World
Aurinia Pharmaceuticals Inc. Added to High Probability Setup ListTechnical Entry Strategy for Beginners Explained - metal.it
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q2 2025 Earnings Call Transcript - Insider Monkey
RBC Raises Price Target on Aurinia Pharmaceuticals to $9 From $8, Keeps Outperform, Speculative Risk - MarketScreener
Aurinia 2025 Q2 Earnings Robust Net Income Growth at 2879.6% - AInvest
Aurinia Pharmaceuticals Inc (AUPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Aurinia Pharmaceuticals (NASDAQ:AUPH) Earns Buy Rating from HC Wainwright - Defense World
Equities Analysts Issue Forecasts for AUPH Q1 Earnings - Defense World
Why Aurinia Pharmaceuticals Inc. stock attracts strong analyst attentionPattern Breakout Prediction for Short Term - Newser
Contradictions in LUPKYNIS and AUR200: Insights from the Latest Earnings Call - AInvest
Aurinia: Q2 Earnings Snapshot - New Haven Register
Aurinia Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aurinia Pharmaceuticals Inc Azioni (AUPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):